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Alzheimer’s disease (AD) is an age‑associated dementia disorder characterized by Aβ plaques and neurofibrillary tangles. 
There is a  strong link between cerebrovascular angiopathy, oxidative stress, inflammation, and glucose metabolism 
abnormalities with the development of AD. In this study, we investigated the therapeutic influences of artemisinin and 
TSP‑1‑human endometrial‑derived stem cells (TSP‑1‑hEDSCs) on the streptozocin‑induced model of AD and diabetes in 
rats. Hippocampal and intraperitoneal injections of streptozocin were used to induce AD and diabetes in male Wistar rats, 
followed by intranasal administration of a single dose of TSP‑1‑hEDSCs and intraperitoneal administration of artemisinin for 
4 weeks. Hematoxylin together with eosin staining was performed for demonstrating Aβ plaque formation and for analyzing 
the influence of treatments on the pyramidal cells in the hippocampus. Biochemical analysis was used to assay the serum 
levels of glucose, MDA, ROS, and TAC. The expression of TNF‑α was measured using real‑time PCR. Streptozocin induced AD 
and diabetes via Aβ plaque formation and increasing blood glucose levels. It also increased the levels of ROS, MDA, and TNF‑α 
and decreased the levels of TAC. Simultaneous or separate administration of artemisinin and TSP‑1‑hEDSCs ameliorated this 
influence by considerably reducing Aβ plaque formation in the hippocampus, reducing glucose, MDA, ROS, and TNF‑α levels, 
and increasing TAC levels. It appears that artemisinin and TSP‑1‑hEDSCs improve the adverse features of AD in a rat model of 
AD and diabetes. Therefore, artemisinin and TSP‑1‑hEDSCs could be utilized as an adjunct treatment, as well as a protective 
agent, in AD patients.
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INTRODUCTION
Alzheimer’s disease (AD) is one of the most com‑
mon types of age‑related dementia, characterized by 
irreversible and devastating neuronal degeneration. 
It slowly destroys memory, cognition, and eventually 
disrupts the ability to perform the simplest daily ac‑
tivities (Alzheimer’s Association, 2014). AD pathology 
occurs along with the aggregation of β‑amyloid pep‑
tide (Aβ) in the spaces between nerve cells as plaques 
and the aggregation of twisted fibers of tau‑hyper‑
phosphorylation protein (p‑tau) inside nerve cells, as 
tau tangles or neurofibrillary tangles. Furthermore, 
increasing evidence suggests chronic inflammation in 
the brain is a fundamental first step in the pathogen‑
esis of AD and increased Aβ and tau structures. Some 
studies have reported an increase of tumor necrosis 
factor‑α (TNF‑α) in AD patients (Heneka and O’Banion, 
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2007; Rubio‑Perez and Morillas‑Ruiz, 2012; Saido, 2013; 
Belluti et al., 2013). It is a potent pro‑inflammatory cy‑
tokine that plays a key role in initiating inflammation 
events. Additionally, the accumulation of plaques leads 
to ongoing neoangiogenesis, increased vascular perme‑
ability, and further hypervascularization (Jefferies et 
al., 2013), and it plays a considerable role in the patho‑
genesis of AD and tissue injury.
AD is strongly correlated to diabetes, leading scien‑
tists to term it type 3 diabetes. According to the Amer‑
ican Diabetes Association, having diabetes is a second 
risk factor in the later progression of AD in older popu‑
lations. Although few studies show a link between cog‑
nitive dysfunction and type 1 diabetes, the majority of 
research has concluded that this correlation between 
diabetes and AD is particular to people with type 2 di‑
abetes (Li et al., 2015). Studies in recent decades have 
shown that insulin resistance and insulin deficiency 
occurs in the brain in both type 2 diabetes and AD re‑
sulting in cognitive dysfunction and AD. Elevated blood 
sugar causes inflammation, and this inflammation may 
damage neurons, deteriorate cognitive function, and 
facilitate AD development (Hoyer 2002; Liu et al., 2011). 
Interestingly, some studies indicate that there is a cor‑
relation between the reduction of brain insulin signal‑
ing and hyperphosphorylation of tau protein (Hoyer 
2002, Liu et al., 2011). Also, individuals with hypergly‑
cemia have a dramatic increase in cerebral β‑amyloid 
protein, which is toxic for nerve cells (de la Monte et 
al., 2012; Chatterjee and Mudher, 2018). Similar to AD, 
perturbations in vasculature have been identified in di‑
abetes mellitus that lead to retinopathy and nephropa‑
thy (Cade, 2008).
Increasing evidence demonstrates that oxidative 
stress has a crucial role in the expansion and progres‑
sion of AD (Sharma and Gupta, 2002). Some studies 
proposed that amyloid‑beta induces lipid peroxide, 
the creation of hydrogen peroxide, inflammatory cy‑
tokines, and superoxide in the brain (Esposito et al., 
2006; Huang et al., 1999). Oxidative stress, through 
the generation of reactive oxygen species (ROS), is the 
main factor in the development of type 2 diabetes mel‑
litus and its related complications (Wright et al., 2006). 
The above described reports lead to the possibility that 
using an antioxidant drug may be helpful in the alle‑
viation of symptoms and complications observed in 
these patients.
In recent years, the use of herbal medicines to 
treat diseases has received much attention due to few‑
er side effects and easy accessibility. Artemisia annua 
(A. annua), also referred to as Shih, is an annual herb 
belonging to the Asteraceae family that is native to 
Asia. Studies have identified that A. annua extract has 
antioxidant, anti‑inflammatory, and anti‑diabetic ac‑
tivity (Ferreira et al., 2010; Helal et al., 2014). The ob‑
jective of this study was to evaluate the protective ef‑
fects of artemisinin, the main therapeutic compounds 
of A. annua, in the rat model of diabetes and AD in com‑
bination with TSP‑1 gene‑transfected human endome‑
trial‑derived stem cells (TSP‑1‑h‑EDSCs). Human EDSCs 
(hEDSCs) are abundant and easily accessible multipo‑
tent stem cells that have the ability to differentiate 
into neuron‑like cells and have the potential for use in 
replacement therapy in the treatment of nervous sys‑
tem degenerative diseases (Wolff et al., 2011). Throm‑
bospondin (TSP)‑1 is an extracellular glycoprotein first 
introduced by Good et al. (1990) as a potent inhibitor 
of angiogenesis. As mentioned above, abnormalities in 
the vasculature are one of the features in both AD and 
diabetes mellitus. 
In the present work, streptozotocin was used to 
develop Alzheimer’s and diabetes in male Wistar rats. 
Streptozotocin is a glucosamine‑nitrosourea com‑
pound that destroys the beta cells of the pancreas and 
widely utilized to develop animal models of diabetes. 
Because Alzheimer’s is associated with impaired glu‑
cose metabolism and diabetes (Virkamäki et al. 1999, 
Hoyer 2002; Cade 2008; Liu et al. 2011; de la Monte, 
2012; Li et al., 2015; Chatterjee and Mudher, 2018) hip‑
pocampal injection of STZ has been widely used by re‑
searchers for inducing AD model in animals, too. This 
model is based on brain resistance to insulin that sim‑
ulates many pathophysiological features of AD, such as 
loss of cognitive function, glucose metabolism abnor‑
malities, free radical generation, apoptosis, neuroin‑
flammation, aggregation of Aβ fragments, and hyper‑
phosphorylation of the microtubule protein tau (Peng 
et al., 2013; Yang et al., 2014). Simultaneously or sep‑
arately administration of artemisinin and TSP‑1‑h‑ED‑
SCs decreased plaque formation, inflammation, and 
stress oxidative through decreasing TNF‑α expression, 
malondialdehyde level (MDA), ROS level, and increas‑
ing total antioxidant capacity (TAC). The blood sugar 
levels also decreased following administration of ar‑
temisinin and TSP‑1‑h‑EDSCs. It seems that artemisi‑
nin and TSP‑1‑hEDSCs improve the adverse features of 
AD in a rat model of Alzheimer’s disease and diabetes. 
Therefore, artemisinin and TSP‑1‑hEDSCs could be uti‑
lized as an adjunct treatment and also as a protective 
agent in Alzheimer’s patients.
METHODS
Animals and treatments
Male Wistar rats (200–220g) were obtained from 
the animal laboratory of Islamic Azad University, Sci‑
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ence and Research Branch, Tehran, and were main‑
tained in the animal house under standard environ‑
mental conditions (room temperature: 22°C, humidi‑
ty: 50±10%, 12‑h light and 12‑h dark cycles). Animals 
had free access to food and water throughout the ex‑
perimental period, under the guidelines for the Care 
and Use of Laboratory Animals (Committee for the 
update of the guide for the care and use of labora‑
tory animals, 1996). The included experiments were 
demonstrated to the Animal Care and Use Commit‑
tee of Islamic Azad University, Science and Research 
Branch to minimize animal suffering and the number 
of animals utilized in the experiments. The animals 
were familiarized with the environmental conditions 
of the animal house for 20 days before starting the 
experiments.
For STZ‑induced AD, animals were anesthetized by 
intraperitoneal (i.p.) injection of urethane (1.5 mg/kg) 
(HTL, China) and placed in the Stoelting stereotaxic 
device (USA) as described previously (Poorgholam et 
al., 2018). Briefly, the stereotaxis measurements were 
‑3.5 mm posterior to the bregma, 2 mm lateral to the 
sagittal suture and 2.8 mm below the dura, based on 
a Paxinos and Watson (1986) atlas. Then, 4 µl STZ 
(3 mg/kg dissolved in saline, Sigma, USA) was slow‑
ly injected into the right dorsal hippocampus within 
2–3 min by a Hamilton microsyringe (5 µl). Following 
injection, the needle was kept in place for about 5 min 
and withdrawn slowly after, ensuring the complete 
distribution of STZ. The rats were kept in an individual 
cage, monitored daily, and given postoperative care for 
7 days. One week after recovery from stereotaxic sur‑
gery, diabetes was induced by a single i.p. injection of 
STZ (30 mg/kg in a citrate buffer with pH=4). Animals 
with a blood sugar level of more than 200 mg/dl were 
considered diabetic. Blood samples were obtained 
from the animal tail vein. Two days after the induction 
of diabetes, TSP‑1 gene‑transfected human endome‑
trial‑derived stem cells (TSP‑1‑hEDSCs) were adminis‑
trated intranasally. The TSP‑1‑hEDSCs were provided 
by Dr. Moradian (Department of Applied Cell Scienc‑
es, Faculty of Medicine, Isfahan University of Medical 
Sciences, Isfahan, Iran) as described previously (Bagh‑
eri‑Mohammadi et al., 2019). For this purpose, a plas‑
tic catheter was linked to a pipette (polyethylene tube; 
BD, Franklin Lakes, NJ) and left in both nasals of the 
rat during deep anesthesia. In order to increase the 
migration of cells to the brain, all rats received 5 µl 
hyaluronidase (Sigma‑Aldrich St. Louis mouse; 100 U 
hyaluronidase dissolved in 24 ml of sterile PBS) before 
cell administration. Then, 10 µl of cell‑containing solu‑
tion were administrated in two steps (5 µl each time) 
and one minute apart for each nasal nostril. In order 
to prevent immune rejection, all animals received cy‑
closporine (through daily water consumption) from 
two days before the stem cell injection to the end of 
the experimental period. Three days after the induc‑
tion of diabetes, animals were treated with artemisinin 
for 4 weeks.
48 rats were divided randomly into six groups (n=8) 
as follows: control group (C) that received standard 
diet and distilled water without surgery and treatment; 
saline treatment (Sal) group which received saline as 
STZ solvent by stereotaxic surgery; AD+D group; rats 
with AD and diabetes at the same time, which received 
i.p. injection of saline (0.3 ml) for 4 weeks; AD+D+art 
group of AD‑diabetes rats that received i.p. injection of 
artemisinin (50 mg/kg) for 4 weeks; AD+D+SC group of 
AD‑diabetes rats, which received intranasally a single 
dose of TSP‑1‑hEDSCs; AD+D+art+SC group: AD‑diabetes 
+ TSP‑1‑hEDSCs rats that obtained i.p. injection of arte‑
misinin (50 mg/kg) for 4 weeks.
Real‑time quantitative PCR
At the end of the fourth week, blood samples were 
gathered from the heart, and leukocytes were isolated 
using lysis buffer. Total RNA was isolated from leuko‑
cytes utilizing the RNX plusTM kit based on the manu‑
facturer’s procedure (Cinnagen, Tehran, Iran). CDNA 
synthesis was performed by EasyTM cDNA Synthesis 
Kit (Parstous Biotechnology, Tehran, Iran) following 
the manufacturer’s instruction. Real‑time PCR was 
carried out by a Bio‑Rad Real‑Time PCR detection sys‑
tem by utilizing SYBR green PCR master mix (Takara, 
Japan). Real‑time PCR was adjusted in different three 
stages: first, initialization under the temperature of 
95°C for 2 min, then denaturation under the tempera‑
ture of 95°C for 5 s, and finally annealing under the 
temperature of 60°C for 30 s (total 56 cycles). PCR 
melting curves were created after real‑time PCR by 
sequential heating of the product to ensure the speci‑
ficity of PCR products. Change in the fold number was 
predicted utilizing the 2‑ΔΔCt approach normalized us‑
ing glyceraldehyde‑3‑phosphate dehydrogenase (GAP‑
DH) as the housekeeping gene. The primer sequences 
used were TNF‑α F: 5´ ACTGAACTTCGGGGTGATTG 3´, 
TNF‑α R: 5´ GCTTGGTGGTTTGCTACGAC 3´, GAPDH F: 
5´ GTATTGGGCGCCTGGTCACC 3´, and GAPDH R: 
5´ CGCTCCTGGAAGATGGTGATGG 3´. All primers were 
synthesized by CinnaGen (Tehran, Iran).
Tissue preparation
Rats were anesthetized terminally by using 
80 mg/kg of ketamine and 10 mg/kg of xylazine and 
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perfused via the left ventricle of the heart with phos‑
phate‑buffered saline (PBS 0.01 M, 200 ml) pH 7.4, 
followed by 4% paraformaldehyde in 0.01 M PBS, pH 
7.4, for fixation. Following perfusion, brains were re‑
moved and postfixed in the identical fixative solution 
for 1 day. Samples were transferred in paraffin and 
sectioned serially at 6‑μm thickness after standard 
tissue processing of clearing and dehydration (from 
2.5 mm to 4.5 mm of the hippocampal formation and 
bregma 2–4 mm of the frontal cortex, as well as from 
10 mm to 15 mm of the cerebellar cortex), placed 
onto glass slides, and covered with hematoxylin and 
eosin (H & E) as described previously (Poorgholam 
et al., 2018). Samples were observed under a light 
microscope. For quantitative analysis, the percent‑
age of plaque area/number of plaques and number 
of neurons were calculated using the ImageJ analysis 
program.
Biochemical analysis
At the end of the fourth week, blood samples were 
obtained from the heart and left at room temperature 
for 2 h. Then, serum samples were collected through 
centrifugation at 2,500×g for 5 min and stored at ‑20°C 
until usage. The level of total antioxidant capacity 
(TAC) and malondialdehyde (MDA), as well as reactive 
oxygen species (ROS) levels, were measured using com‑
mercial ELISA kits (Zellbio GmbH, Ulm, Germany) based 
on the instructions of the manufacturer. The concen‑
tration of blood glucose was estimated by commercial 
spectrophotometric assay kits (Pars Azmun Company, 
Tehran, Iran) based on the recommendations of the 
manufacturer.
Statistical analysis
The data are presented as the means±S.E.M. 
One‑way ANOVA with Tukey’s post hoc test, was used 
for comparing between groups. All data were ana‑
lyzed by SPSS software version 17.0. The charts were 
drawn using Microsoft Excel 2010. P<0.05 was set as 
significant.
RESULTS 
Hippocampal and intraperitoneal injections of STZ 
were used for the experimental model of developing 
AD and diabetes. In rats, H & E staining was used for 
demonstrating the formation of Aβ plaques and the 
development of AD after STZ injection. Comparison 
of brain tissues from different animal groups revealed 
apparent histological changes in the rat hippocampus. 
Table I summarizes the number of Aβ plaques and the 
number of neurons in all animal groups. No Aβ plaques 
or neuronal death were observed in the control rats 
(Fig. 1, C1 and C2), while other animals showed percent‑
ages of neuronal death and Aβ plaque formation. Sec‑
tions of the hippocampus in control rats showed normal 
brain histology along with regular distribution of clear 
pyramidal cells that had distinct nuclei as revealed by 
H & E staining. Extensive histological changes, such as 
the formation of Aβ plaque (black arrows), and neuro‑
nal cell death were observed in the hippocampus in the 
AD‑diabetes group (Fig. 1, AD+D) compared to the con‑
trol group, which indicated development of AD. Simul‑
taneous or separate administration of artemisinin and 
TSP‑1‑hEDSCs ameliorated histological changes in the 
AD‑diabetes‑artemisinin (Fig. 1, AD+D+art), AD‑diabe‑
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Table I. Number of plaques and neurons in the CA1 and cortex area of hippocampus.


























(*) statistically distinct from the control rats at P≤0.05; (**) statistically distinct from the control rats at P≤0.01; (#) statistically distinct from the AD+D group (P≤0.05); (##) statistically 
distinct from the AD+D group (P≤0.01). (b) statistically different from the AD+D+SC group (P≤0.05). C: control rats; AD+D: AD‑diabetes rats; AD+D+art: AD‑diabetes‑artemisinin 
rats; AD+D+SC: AD‑diabetes‑TSP‑1‑hEDSCs rats; AD+D+art+SC: AD‑diabetes‑artemisinin‑TSP‑1‑hEDSCs rats.
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tes‑TSP‑1‑hEDSCs (Fig. 1, AD+D+SC), and AD‑diabetes‑ar‑
temisinin‑TSP‑1‑hEDSCs (Fig. 1, AD+D+art+SC) groups. 
The number of Aβ plaques, and amount of neuronal 
cell death were decreased in AD‑diabetes‑artemisinin 
(Fig. 1, AD+D+art), AD‑diabetes‑TSP‑1‑hEDSCs (Fig. 1, 
AD+D+SC), and AD‑diabetes‑artemisinin‑TSP‑1‑hEDSCs 
(Fig. 1, AD+art+SC) groups in comparison to the AD‑di‑
abetes (AD+D) group. Therefore, simultaneous or sep‑
arate administration of artemisinin and TSP‑1‑hEDSCs 
decreased the adverse histological changes in AD rats.
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Fig. 1. Photomicrograph of hippocampus of control, 100X (C1); control, 400X (C2); AD‑diabetes, 400X (AD+D); AD‑diabetes+artemisinin, 400X (AD+D+art); 
AD‑diabetes‑TSP‑1‑hEDSCs, 400X (AD+D+SC); and AD‑diabetes‑artemisinin‑TSP‑1‑hEDSCs, 400X (AD+D+art+SC) groups. Black arrows show live neurons 
and Aβ plaques in C2 and AD sections, respectively.
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Effect of artemisinin treatment  
on serum glucose
In order to evaluate the induction of diabetes and 
the effect of artemisinin or TSP‑1‑hEDSCs on diabetes, 
blood serum glucose was measured at the end of the 
fourth week for all experimental groups and the results 
are presented in Fig. 2. Our results revealed a marked 
increase (2.7 fold) in the level of blood serum glucose 
in the AD+D group (AD‑diabetes rats) compared with 
controls (P≤0.01). Artemisinin or TSP‑1‑hEDSC treat‑
ment significantly decreased the blood glucose level of 
AD+D+art (AD‑diabetes‑artemisinin rats) and AD+D+SC 
(AD‑diabetes‑TSP‑1‑hEDSCs rats) groups. Simultaneous 
administration of artemisinin and TSP‑1‑hEDSCs re‑
duced the blood glucose level in the AD+D+art+SC group 
(AD‑diabetes‑artemisinin‑TSP‑1‑hEDSCs rats) to con‑
trol levels by the end of the experiments. Therefore, si‑
multaneous or separate administration of artemisinin 
and TSP‑1‑ hEDSCs improved the blood glucose level in 
AD‑diabetes rats.
Effect of artemisinin treatment on serum levels 
of MDA, ROS, and TAC
Oxidative stress plays a crucial role in the expan‑
sion and progression of AD and diabetes. The serum 
levels of MDA, ROS, and ROS (Fig. 2) were assayed to 
evaluate the therapeutic effect of artemisinin and 
TSP‑1‑hEDSCs on the prevention of oxidative stress 
in AD and diabetes animals. The levels of blood se‑
rum MDA were assessed at the end of the fourth week 
for all animal groups. Fig. 2 shows that the levels of 
MDA in the AD‑diabetes rats (AD+D) significantly in‑
creased up to 2‑fold versus the control (C group) lev‑
els (P≤0.05). Simultaneous or separate administra‑
tion of artemisinin and TSP‑1‑hEDSCs significantly 
decreased MDA levels in the AD‑diabetes‑artemisinin 
(AD+D+art), AD‑diabetes‑TSP‑1‑hEDSCs (AD+D+SC), and 
AD‑diabetes‑artemisinin‑TSP‑1‑hEDSCs (AD+D+art+SC) 
groups in comparison to the AD+D group. Fig. 2 shows 
the level of ROS in serum samples of all experimental 
groups, taken at the end of the fourth week. A marked 
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Fig. 2. The serum level of glucose, MD, ROS, and TAC. Values are presented as mean ± SE (n=8/each group). (*) statistically distinct from the control rats 
at P≤0.05; (**) statistically distinct from the control rats at P≤0.01; (#) statistically distinct from the AD+D group (P≤0.05); (##) statistically distinct from the 
AD+D group (P≤0.01). (a) statistically different from the AD+D+art group (P≤0.05); (b) statistically different from the AD+SC group (P≤0.05). C: control rats; 
Sal: saline treatment group; AD+D: AD‑diabetes rats; AD+D+art: AD‑diabetes‑artemisinin rats; AD+D+SC: AD‑diabetes‑TSP‑1‑hEDSCs rats; AD+D+art+SC: 
AD‑diabetes‑artemisinin‑TSP‑1‑hEDSCs rats.
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increase (up to 2.5 fold) was found in the serum ROS 
levels for the AD‑diabetes (AD+D) group compared 
with the control (C) group (P≤0.01). Artemisinin or 
TSP‑1‑hEDSC treatment significantly decreased the 
serum ROS levels of the AD‑diabetes‑artemisinin 
(AD+D+art) and AD‑diabetes‑TSP‑1‑hEDSCs (AD+D+SC) 
groups (P≤0.05). Simultaneous administration of ar‑
temisinin and TSP‑1‑hEDSCs reduced the blood ROS 
levels of the AD‑diabetes‑artemisinin+TSP‑1‑hEDSCs 
(AD+D+art+SC) group to the control levels by the end 
of the experiments. As presented in Fig. 2, the TAC in 
the AD‑diabetes rats significantly decreased up to 2.5 
fold compared to control (C group) levels (P≤0.01). Si‑
multaneous or separate administration of artemisinin 
and TSP‑1‑hEDSCs significantly increased the TAC of 
the AD‑diabetes‑artemisinin (AD+D+art), AD‑diabe‑
tes‑TSP‑1‑hEDSCs (AD+D+SC), and AD‑diabetes‑arte‑
misinin‑TSP‑1‑hEDSCs (AD+D+art+SC) groups in com‑
parison to the AD‑diabetes (AD+D) group. Adminis‑
tration of artemisinin, alone or in combination with 
TSP‑1‑hEDSCs, significantly increased the TAC of the 
AD‑diabetes‑artemisinin (AD+D+art) and AD‑diabe‑
tes‑artemisinin‑TSP‑1‑hEDSCs (AD+D+art+SC) groups, 
respectively. The TAC of AD‑diabetes‑artemisinin 
(AD+D+art) and AD‑diabetes‑artemisinin‑TSP‑1‑hED‑
SCs (AD+D+art+SC) rats reached the control levels by 
the end of the experiments. Therefore, simultane‑
ous or separate administration of artemisinin and 
TSP‑1‑hEDSCs improved the serum levels of MDA, ROS, 
and TAC in AD‑diabetes rats.
TNF‑α gene expression
Here, we investigated the gene expression for 
tumor necrosis factor‑α (TNF‑α) using real‑time 
qRT‑PCR (Fig. 3). It is a potent pro‑inflammatory cy‑
tokine that plays a key role in initiating inflamma‑
tion events. Inflammation has an important role in 
the pathogenesis of AD and diabetes. The results in‑
dicated that expression of TNF‑α in the AD‑diabetes 
rats (AD+D group) significantly increased up to 3‑fold 
of the control (C group) levels (P≤0.01), but simulta‑
neous or separate administration of artemisinin and 
TSP‑1‑hEDSCs were able to significantly alleviate the 
effects of AD and diabetes. The expression of TNF‑α 
significantly decreased after administration of ar‑
temisinin or TSP‑1‑hEDSCs in the AD‑diabetes‑arte‑
misinin (Fig. 3, AD+D+art), AD‑diabetes‑TSP‑1‑hED‑
SCs (Fig. 3, AD+D+SC), and AD‑diabetes‑artemisi‑
nin‑TSP‑hEDSCs (Fig. 3, AD+D+art+SC) groups in com‑
parison to the AD‑diabetes (AD+D) group. Therefore, 
simultaneous or separate administration of artemisi‑
nin and TSP‑1‑hEDSCs improved the expression of the 
TNF‑α (pro‑inflammatory cytokine) gene in AD‑diabe‑
tes rats.
DISCUSSION
In this study, we showed that hippocampal and 
i.p. injections of STZ could induce AD and diabetes 
in male Wistar rats via Aβ plaque formation and in‑
creased blood glucose levels and neuronal cell death. 
It increased the levels of ROS, MDA, and TNF‑α and de‑
creased the TAC. Simultaneous or separate adminis‑
tration of artemisinin and TSP‑1‑hEDSCs ameliorated 
these features by a considerably reducing Aβ plaque 
formation and neuronal cell death in the hippocam‑
pus, reducing glucose, MDA, ROS, and TNF‑α levels in 
serum, and increasing TAC.
Hippocampal and i.p. injections of STZ were used 
for the experimental model of AD and diabetes devel‑
opment. Based on the results, extensive histological 
changes, such as the formation of Aβ plaques and neu‑
ronal cell death were observed in the hippocampus in 
the AD‑diabetes group (AD+D), which indicated that 
the AD model was successfully established. The level 
of blood serum glucose in EXP‑1 animals significantly 
increased and was more than 200 mg/dl, indicating the 
successful induction of diabetes in rats.
The biochemical findings were in line with the 
histological data and induction of AD and diabetes 
in AD‑diabetes animals. The level of ROS and MDA 
in serum samples of EXP‑1 animals was significantly 
higher compared with control rats. MDA and ROS are 
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Fig. 3. Gene expression of TNF‑α using real‑time qRT‑PCR (n=8/each group). 
(*) statistically different from the control rats (P≤0. 05); (**)  statistically 
different from the control rats (P≤0.01); (#) statistically different from the 
AD+D group (P≤0.05); (a) statistically different from the AD+D+art group 
(P≤0.05); (b) statistically different from the AD+D+SC group (P≤0.05). C: control 
rats; Sal: saline treatment group; AD+D: AD‑diabetes rats; AD+D+art: 
AD‑diabetes‑artemisinin rats; AD+D+SC: AD‑diabetes‑TSP‑1‑hEDSCs rats; 
AD+D+art+SC: AD‑diabetes‑artemisinin‑TSP‑1‑hEDSCs rats.
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known oxidative stress biomarkers. Oxidative stress 
refers to an increase in ROS levels due to an imbal‑
ance between ROS formation and the antioxidant sys‑
tem ability to neutralize them. Oxidative stress has an 
important role in the development and progression 
of age‑related neurodegenerative disease and cogni‑
tive abnormality, such as AD, and it can promote the 
production of Aβ plaques (Sharma and Gupta, 2002). It 
has been shown that decreased antioxidant defenses 
in the brain can lead to memory impairment by affect‑
ing synaptic function and neurotransmission in older 
populations (Tönnies and Trushina, 2017). The brain’s 
structure is largely composed of lipids and its physi‑
ology relies highly on glucose metabolism (Hamilton 
et al., 2007). Therefore, increasing ROS production can 
easily result in oxidized brain lipids and affect synap‑
tic activity. 
In this study, observation of Aβ plaques in the hip‑
pocampus of AD‑diabetes rats was associated with in‑
creased serum levels of oxidative stress biomarkers 
such as MDA and ROS, which suggests a role for oxi‑
dative stress in AD. Oxidative stress was also shown 
to be the primary factor in the promotion of insulin 
resistance, β‑cell impairment, glucose metabolism 
disorder, and type 2 diabetes mellitus (Wright et al., 
2006). Reports of TAC in AD are contradictory. While 
Moslemnezhad et al. (2016) observed a decrease in 
plasma TAC levels in AD patients, no significant dif‑
ferences in plasma TAC levels were detected by Foy 
et al. (1999) and Sinclair et al. (1999) between AD pa‑
tients and controls. In the present study, the observed 
significant decrease in serum TAC levels in the AD+D 
group (AD‑diabetes rats) compared to controls is in 
line with the results of Moslemnezhad et al. (2016) and 
re‑emphasizes the concept of induced oxidative stress 
in animals.
AD is recognized by three hallmarks: accumulation 
of Aβ plaques, accumulation of tau‑hyperphosphory‑
lation protein, and chronic inflammation (Heneka and 
O’Banion, 2007; Rubio‑Perez and Morillas‑Ruiz, 2012; 
Saido, 2013; Belluti et al., 2013). TNF‑α is an important 
pro‑inflammatory cytokine, which is associated with 
neurodegenerative disorders like AD. It is the first ini‑
tiator of immune‑mediated inflammation in the brain 
that induces microglial activation and leads to neuro‑
nal death (Janelsins et al., 2008). Studies have shown 
that the level of TNF‑α is higher in plasma and brain 
of AD patients in comparison to normal individuals 
(Swardfager et al., 2010). The results of the present 
study confirmed an increase in TNF‑α expression in 
an AD model. Therefore, the observed significant in‑
crease in the mRNA expression of TNF‑α in the AD rats 
(AD+D group) compared to controls is in line with the 
findings of other studies.
Due to the role of oxidative stress and ROS mole‑
cules in the etiology of AD, antioxidant therapies have 
received a great deal of attention in recent decades. In 
this study, protective treatment with artemisinin im‑
proved histological changes and biochemical parame‑
ters. Artemisinin is a primary therapeutic compound 
of A. annua with antioxidant, anti‑inflammatory, and 
anti‑diabetic activity (Ferreira et al., 2010; Helal et 
al., 2014). Administration of artemisinin significant‑
ly reduced glucose, MDA, ROS, and TNF‑α levels in the 
AD‑diabetes‑artemisinin group, indicating the anti‑di‑
abetic, antioxidant, and anti‑inflammatory effects of 
artemisinin. Also, TAC levels significantly increased 
following artemisinin usage in the AD‑diabetes‑arte‑
misinin group rats and reached the control levels, con‑
firming an antioxidant function of artemisinin.
Brain tissue from the AD‑diabetes‑artemisinin group 
showed a decrease in the number of Aβ plaques and 
neuronal cell death compared to the control rats, posi‑
tively supporting the idea of treatment of AD with anti‑
oxidants. Zhao et al. (2020) found that artemisinin could 
reduce Aβ plaques and tau protein in a 3xTg AD mouse 
model. They also showed that artemisinin could reduce 
apoptosis and neuronal cell death and could stimulate 
the activation of the ERK/CREB signaling pathway.
In the present study, besides artemisinin, the ther‑
apeutic effect of TSP‑1‑hEDSCs was also investigated. 
Mesenchymal stem cell (MSC) transplantation has 
already been used for the treatment of central ner‑
vous system disorders, including AD. Cui et al. (2017) 
reported that human umbilical cord mesenchymal 
stem cells can improve cognitive ability in a mouse 
model of AD by reducing oxidative stress and increas‑
ing neurogenesis in the hippocampus and enhancing 
expression of proteins related to neuronal synaptic 
plasticity. HEDSCs are MSCs that represent a new and 
valuable source of stem cells in regenerative medicine 
and clinical application. These cells have comprehen‑
sive advantages as opposed to other stem cells due to 
their high proliferation rate, easy periodic collection 
in a non‑invasive manner, high multi‑differentiation 
potential, low immunogenic properties, reduced in‑
flammatory properties, and low tumorigenicity (In‑
dumathi et al., 2013). In the past decade, in vitro dif‑
ferentiation of EDSCs into such neural cells has been 
shown (Wolff et al., 2011). Zhao et al. (2018) showed 
that intracerebral transplantation of EDSCs can im‑
prove memory and cognitive function in a mouse 
model of AD. They found that EDSCs can reduce the 
number of Aβ plaques and tau hyperphosphorylation, 
increase Aβ degrading enzymes, and regulate pro‑in‑
flammatory cytokines in the brain. In another study, 
Bagheri‑Mohammadi et al. (2019) used EDSCs for Par‑
kinson’s disease (PD) treatment. They showed that 
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non‑invasive intranasal administration of hEDSCs 
could improve the behavioral parameters and amelio‑
rate the PD symptoms in a mouse model of PD (Wu 
and Finley, 2017). 
In the present investigation, the impact of hEDSCs 
transfected with the TSP‑1 gene on the treatment of 
AD was studied. TSPs‑1 is an extracellular glycoprotein 
first introduced by Good et al. (1990) as a potent inhibi‑
tor of angiogenesis. It is a member of the thrombospon‑
din family that mediates cell‑to‑cell and cell‑to‑matrix 
interactions. It is involved in various biological pro‑
cesses such as angiogenesis and regulation of immune 
response. This protein can bind to multiple receptors, 
including CD36 and CD47. It is well known that the an‑
ti‑angiogenesis activity of TSP‑1 is due to it binding to 
endothelial cells via the CD34 receptor. This leads to the 
expression of FAS ligand, activation of FAS receptor, ac‑
tivation of caspases, and finally induction of endothe‑
lial cell apoptosis (Lopez‑Dee et al., 2011). One feature 
of AD is neoangiogenesis and increased vascular per‑
meability due to the accumulation of amyloid plaques 
(Jefferies et al., 2013). Therefore, pharmacological in‑
terventions that target angiogenesis may be beneficial 
and effective AD therapy. 
The results of the present study indicated that in‑
tranasal administration of TSP‑1‑hEDSCs can improve 
the histological changes in the brain and biochemical 
changes in the serum in the STZ‑induced AD mod‑
el. Aβ plaque was decreased in the AD+D+SC group 
(AD‑diabetes + TSP‑1‑hEDSCs) and the levels of neu‑
ronal cell death were decreased in these animals in 
comparison to the AD‑diabetes group. Furthermore, 
the expression of TNF‑α significantly decreased after 
administration ofTSP‑1‑hEDSCs in the AD+SC rats in 
comparison to the AD‑diabetes group. These findings 
are in line with Zhao et al.’s (2018) studies and may 
confirm the impact of EDSCs in decreasing Aβ plaques 
and regulating pro‑inflammatory cytokines in the 
brain. Improvement of AD symptoms in AD+D+SC rats 
may also be caused by TSP‑1 administration. Supple‑
mentary studies and simultaneously and separately 
administered EDSCs and TSP‑1 are needed to distin‑
guish the impact of EDSCs from TSP‑1 for AD therapy. 
Decreased TNF‑α expression in AD+D+SC animals may 
be due to the anti‑inflammatory function of TSP‑1 
protein (Lopez‑Dee et al., 2011). Moreover, treatment 
with TSP‑1‑hEDSCs also improved the serum levels 
of ROS, TAC, and MDA. Therefore, it can be suggested 
that TSP‑1‑hEDSCs can reduce the pathophysiological 
features of AD.
Administration of TSP‑1‑hEDSCs also decreased the 
level of serum glucose in AD+D+SC groups. As men‑
tioned above, there is a strong correlation between 
cognitive dysfunction and diabetes. Previous studies 
have shown that elevated blood sugar causes inflam‑
mation that can lead to neuronal death and develop‑
ment of AD (Hoyer 2002, Liu et al., 2011). Therefore, 
controlling blood sugar levels may be effective in re‑
ducing and improving AD symptoms. These findings 
again emphasize the therapeutic effect of EDSCs and 
TSP‑1 for AD.
The effect of simultaneous administration of 
artemisinin and TSP‑1‑hEDSCs was also studied 
(AD+D+art+SC group). The data indicated that simul‑
taneous application of artemisinin and TSP‑1‑hEDSCs 
further decreased the serum levels of glucose and MDA 
and the mRNA expression of TNF‑α in the AD+D+art+SC 
animals. The data showed that the levels of glucose 
and ROS in AD+D+art+SC rats reached control levels 
by the end of the experiments. These findings suggest 
that successful treatment of AD may not be achieved 
with just a single pharmacological intervention and it 
may be better to target two or more pathophysiologi‑
cal features simultaneously.
CONCLUSION
In this study, hippocampal and i.p. injections of 
STZ were used to induce AD and diabetes in male Wis‑
tar rats, respectively. The model was able to achieve 
a number of AD features, such as inducing oxidative 
stress, inflammation, hyperglycemia, aggregation of 
Aβ plaques, and neuronal cell death and degeneration. 
Separately or simultaneously administered artemisinin 
and TSP‑1‑h‑EDSCs could prevent adverse features of 
the disease. The application was able decrease plaque 
formation, inflammation, and degeneration in the 
hippocampus. Additionally, it led to an improvement 
in the levels of serum glucose, a marker of oxidative 
stress, and mRNA levels of the pro‑inflammatory fac‑
tor, TNF‑α. Therefore, in the case of age‑related neuro‑
degenerative diseases like AD and Parkinson’s disease, 
artemisinin, EDSCs, and TSP‑1 protein might be utilized 
as protective agents and/or adjunct treatments. Fur‑
ther studies will be important for distinguishing the 
impact of EDSCs from TSP‑1 and for establishing the 
clinical application of anti‑angiogenic agents for suc‑
cessful AD therapy.
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